CareDx Stock Price, News & Analysis (NASDAQ:CDNA)

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CareDx in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CDNA shares.
View CDNA analyst ratings or view top-rated stocks.

6 brokerages have issued 12-month price objectives for CareDx's shares. Their CDNA share price targets range from $9.00 to $25.00. On average, they predict the company's stock price to reach $13.80 in the next year. This suggests a possible upside of 41.8% from the stock's current price.
View analysts price targets for CDNA or view top-rated stocks among Wall Street analysts.

CareDx's stock was trading at $11.41 on January 1st, 2023. Since then, CDNA shares have decreased by 14.7% and is now trading at $9.73.
View the best growth stocks for 2023 here.

CareDx saw a drop in short interest in November. As of November 15th, there was short interest totaling 3,890,000 shares, a drop of 13.6% from the October 31st total of 4,500,000 shares. Based on an average trading volume of 957,600 shares, the short-interest ratio is presently 4.1 days. Approximately 7.5% of the company's stock are sold short.
View CareDx's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024.
View our CDNA earnings forecast.

CareDx, Inc (NASDAQ:CDNA) announced its earnings results on Wednesday, November, 8th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.38) by $0.06. The business had revenue of $67.19 million for the quarter, compared to analyst estimates of $53.14 million. CareDx had a negative trailing twelve-month return on equity of 21.94% and a negative net margin of 30.46%. The firm's quarterly revenue was down 15.3% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.32) earnings per share.

ETFs with the largest weight of CareDx (NASDAQ:CDNA) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), Jacob Forward ETF (JFWD), ROBO Global Healthcare Technology and Innovation ETF (HTEC) and Global X Genomics & Biotechnology ETF (GNOM).First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).

CareDx issued an update on its FY 2023 earnings guidance on Wednesday, November, 1st. The company provided EPS guidance of for the period. The company issued revenue guidance of $274.00 million-$278.00 million, compared to the consensus revenue estimate of $255.42 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other CareDx investors own include Block (SQ), Roku (ROKU), Exact Sciences (EXAS), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Enphase Energy (ENPH), Johnson & Johnson (JNJ), Activision Blizzard (ATVI) and Alibaba Group (BABA).

CareDx's stock is owned by a number of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (12.33%), Sumitomo Mitsui Trust Holdings Inc. (5.58%), Armistice Capital LLC (3.76%), Kent Lake Capital LLC (2.54%), Jacobs Levy Equity Management Inc. (2.08%) and First Eagle Investment Management LLC (1.86%). Insiders that own company stock include Ankur Dhingra, George Bickerstaff, Grace Colon, Michael Goldberg, Paul Adler, Peter Maag, Ralph Snyderman, Reginald Seeto, Sasha King, Thomas A Thomas and William A Hagstrom.
View institutional ownership trends.

Shares of CDNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.